The presence of meniscal lesions is a strong predictor of neuropathic pain in symptomatic knee osteoarthritis: a cross-sectional pilot study

Table 1 Demographic and clinical characteristics of patients based on PainDETECT score

	PainDETECT ≤12 n = 25	PainDETECT 13-18 n = 9	PainDETECT ≥19 n = 16	Pvalue
Demographic and clinical
Age, years	66 ± 9	63 ± 9	67 ± 7	0.392*
Female, n (%)	18 (72%)	5 (56%)	10 (63%)	0.629‡
Weight, kg	82.5 ± 14.1	81.0 ± 10.6	87.0 ± 18.9	0.587*
OA duration, years	7.7 ± 8.1	7.4 ± 6.6	8.1 ± 4.6	0.528*
BMI, kg/m²	31 ± 6	29.9 ± 3	33 ± 6	0.558*
NSAID users, n (%)	3 (12%)	0 (0%)	5 (31%)	0.114¶
PainDETECT	8.1 ± 2.6	15.6 ± 1.1	24.2 ± 4.2	<0.001♦
WOMAC
Pain (0–100)	43 ± 17	50 ± 13	65 ± 14	<0.001♦
Function (0–100)	45 ± 23	52 ± 15	68 ± 14	<0.001♦
Stiffness (0–100)	51 ± 24	49 ± 18	69 ± 16	0.007♦
Total (0–100)	45 ± 21	51 ± 14	68 ± 13	<0.001♦
VAS pain (0–100 mm)	62 ± 14	62 ± 13	69 ± 13	0.023♦
Kellgren-Lawrence score				0.068†§
2	14 (56%)	5 (56%)	5 (31%)
3	11 (44%)	4 (44%)	11 (69%)
Inflammatory biomarkers
Sedimentation rate, mm	12.4 ± 9.0	12.6 ± 5.5	15.2 ± 20.8	0.406♦
CRP, mg/l	4.3 ± 2.9	6.8 ± 9.1	5.0 ± 4.7	0.432♦

Results are shown as mean ± standard deviation (SD) unless otherwise indicated. P values were assessed using the *Kruskal-Wallis test, the ‡chi-square test, the ¶Fisher’s exact test, the ♦ Jonckheere-Terpstra test for trend, or the †Cochran-Armitage trend test; §Includes both Kellgren-Lawrence scores. n, number of participants; OA, osteoarthritis; BMI, body mass index; NSAID, non-steroidal anti-inflammatory drug; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index (each subscale, 100 = worst score; total scale, 100 = worst score); VAS, visual analog scale (0 mm = no pain, 100 mm = most severe pain); CRP, C-reactive protein.

ISSN: 1478-6362